IGF-1 DES vs Orexin-A
Head-to-head comparison of IGF-1 DES (Des(1-3) Insulin-like Growth Factor 1) and Orexin-A (Hypocretin-1 (Orexin-A)) — benefits, dosing, side effects, research data, and where to buy.
| Property | IGF-1 DES | Orexin-A |
|---|---|---|
| Category | Growth Hormone | Cognitive Enhancement |
| Full Name | Des(1-3) Insulin-like Growth Factor 1 | Hypocretin-1 (Orexin-A) |
| Molecular Weight | 7365 Da | 3562 Da |
| Half-Life | ~20-30 minutes | Minutes to <1 hour |
| Amino Acids | 67 | 33 |
| Typical Dose | — | Research-only; no validated human dose |
| Route | — | Intracerebroventricular/Intranasal |
| Purity | >98% | ≥98% |
| Studies Count | 65 | 42 |
| Research Status | Active Research | Pre-clinical |
IGF-1 DES Benefits
- ✓Highly potent localized muscle growth, enhanced protein synthesis, satellite cell proliferation, does not bind to IGFBPs, rapid onset
Orexin-A Benefits
- ✓wakefulness
- ✓attention
- ✓memory consolidation
- ✓fatigue resistance
IGF-1 DES Dosing
50-150 mcg per injection site bilaterally post-workout. 4-6 week cycles due to potency. Multiple daily injections in research.
Orexin-A Dosing
Research-only i.c.v. microgram/nanomolar studies|intranasal experimental use|no established human protocol
IGF-1 DES Side Effects
- ⚠Hypoglycemia (dose-dependent), localized swelling, shorter duration limits systemic exposure compared to IGF-1 LR3.
Orexin-A Side Effects
- ⚠insomnia
- ⚠headache
- ⚠blood pressure changes
Research Overview
IGF-1 DES
Missing first three amino acids (Gly-Pro-Glu) eliminates IGFBP binding, resulting in 100% bioavailable IGF-1R stimulation. Activates PI3K/Akt/mTOR for protein synthesis and satellite cell proliferation.
Orexin-A
Preclinical studies link orexin signaling to arousal, learning, and memory consolidation, making orexin-A a candidate for cognition-related research. It is not an approved cognitive enhancer and remains an experimental peptide.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.